Probiotics in health maintenance and disease prevention

Alternative Medicine Review

Volumn 8, Issue 2, 2003, Pages 143-155

  Drisko, Jeanne A ^a,b   Giles, Cheryl K ^c,d   Bischoff, Bette J ^c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b Univ of Kansas School of Medicine ^*  (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d Northeast Iowa Family Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; DISEASE COURSE; DRUG EFFECT; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOREGULATION; INFLAMMATORY DISEASE; MICROFLORA; NONHUMAN; NUTRITIONAL VALUE; PATHOGENESIS; PROPHYLAXIS; REVIEW; UPREGULATION;

DIGESTIVE SYSTEM; HUMANS; PREVENTIVE MEDICINE; PROBIOTICS;

EID: 0037673962     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. McFarland LV. Beneficial microbes: health or hazard? Eur J Gastroenterol Hepatol 2000;12:1069-1071.
2. Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000;15:489-493.
3. Lucchini F, Kmet V, Cesena C, et al. Specific detection of a probiotic Lactobacillus strain in faecal samples by using multiplex PCR. FEMS Microbiol Lett 1998;158:273-278.
4. Vanderhoof JA. Probiotics and intestinal inflammatory disorders in infants and children. J Pediatr Gastroenterol Nutr 2000;30:S34-S38.
5. Bengmark S. Colonic food: pre- and probiotics. Am J Gastroenterol 2000;95:S5-S7.
6. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-639.
7. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology 1999;116:1246-1249.
8. Caplan MS, Jilling T. Neonatal necrotizing enterocolitis: possible role of probiotic supplementation. J Pediatr Gastroenterol Nutr 2000;30:S18-S22.
9. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-309.
10. Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000;95:S2-S4.
11. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-1464.
12. Kyne L, Kelly CP. Recurrent Clostridium difficile diarrhoea. Gut 2001;49:152-153.
13. Levy J. The effects of antibiotic use on gastrointestinal function. Am J Gastroenterol 2000;95:S8-S10.
14. Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999;276:G941-G950.
15. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997;99:179-185.
16. Walker WA. Role of nutrients and bacterial colonization in the development of intestinal host defense. J Pediatr Gastroenterol Nutr 2000;30:S2-S7.
17. Vanderhoof JA, Young RJ. Use of probiotics in childhood gastrointestinal disorders. J Pediatr Gastroenterol Nutr 1998;27:323-332.
18. Gorbach SL, Goldin BR. Nutrition and the gastrointestinal microflora. Nutr Rev 1992;50:378-381.
19. Sarem-Damerdji L, Sarem F, Marchal L, Nicolas JP. In vitro colonization ability of human colon mucosa by exogenous Lactobacillus strains. FEMS Microbiol Lett 1995;131:133-137.
20. Percival M. Choosing a probiotic supplement. Clin Nutr Insights 1997;6:1-4.
21. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001;292:1115-1118.
22. Vanderhoof JA. Probiotics: future directions. Am J Clin Nutr 2001;73:1152S-1155S.
23. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-1114.
24. Marteau PR, de Vrese M, Cellier CJ, Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;73:430S-436S.
25. Aiba Y, Suzuki N, Kabir AM, et al. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol 1998;93:2097-2101.
26. Malin M, Verronen P, Korhonen H, et al. Dietary therapy with Lactobacillus GG, bovine colostrums or bovine immune colostrums in patients with juvenile chronic arthritis: evaluation of effect of gut defense mechanisms. Inflammopharmacology 1997;5:219-236.
27. Murch SH. Toll of allergy reduced by probiotics. Lancet 2001;357:1057-1059.
28. Pelto L, Isolauri E, Lilius EM, et al. Probiotic bacteria down-regulate the milk-induced inflammatory response in milk-hypersensitive subjects but have an immunostimulatory effect in healthy subjects. Clin Exp Allergy 1998;28:1474-1479.
29. Pessi T, Sutas Y, Marttinen A, Isolauri E. Probiotics reinforce mucosal degradation of antigens in rats: implications for therapeutic use of probiotics. J Nutr 1998;128:2313-2318.
30. Pessi T, Sutas Y, Hurme M, Isolauri E. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin Exp Allergy 2000;30:1804-1808.
31. Cunningham-Rundles S, Ahrne S, Bengmark S, et al. Probiotics and immune response. Am J Gastroenterol 2000;95:S22-S25.
32. Wagner RD, Warner T, Roberts L, et al. Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect Immun 1997;65:3345-3351.
33. Sanders ME, Klaenhammer TR. Invited review: the scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci 2001;84:319-331.
34. No authors listed. Lactobacillus sporogenes monograph. Altern Med Rev 2002;7:340-342.
35. De Santis A, Famularo G, De Simone C. Probiotics for the hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 2000;95:323-324.
36. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotovirus. Lancet 1994;344:1046-1049.
37. Shornikova AV, Casas IA, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997;24:399-404.
38. Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol 2000;95:S16-S18.
39. Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000;95:S11-S13.
40. Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000;95:S19-S21.
41. Szajewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001;138:361-365.
42. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987;2:1519.
43. Biller JA, Katz AJ, Flores AF, et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995;21:224-226.
44. LaMont JT. The renaissance of probiotics and prebiotics. Gastroenterology 2000;119:291.
45. McFarland LV. Re: probiotics and C. Difficile diarrhea. Am J Gastroenterol 2000;95:2128.
46. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-1017.
47. Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998;27:155-160.
48. Bazzoli F, Zagari RM, Fossi S, et al. In vivo Helicobacter pylori clearance failure with Lactobacillus acidophilus. Gastroenterology 1992;102:A38.
49. Cadieux P, Burton J, Gardiner G, et al. Lactobacillus strains and vaginal ecology. JAMA 2002;287:1940-1941.
50. Moore WE, Moore LH. Intestinal floras of populations that have a high risk of colon cancer. Appl Environ Microbiol 1995;61:3202-3207.
51. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1238.
52. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000;289:1352-1355.
53. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-635.
54. Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea, and in the treatment of acute diarrhoea. J Int Med Res 1989;17:333-338.
55. Mitra AK, Rabbani GH. A double-blind, controlled trial of bioflorin (Streptococcus faecium SF68) in adults with acute diarrhea due to Vibrio cholerae and enterotoxigenic Escherichia coli. Gastroenterology 1990;99:1149-1152.
56. Floch MH, Moussa K. Probiotics and dietary fiber: the clinical coming of age of intestinal microecology. J Clin Gastroenterol 1998;27:99-100.
57. Guarino A, Canani RB, Spagnuolo MI, et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997;25:516-519.
58. Sheih YH, Chiang BL, Wang LH, et al. Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium Lactobacillus rhamnosus HN001. J Am Coll Nutr 2001;20:149-156.
59. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001;69:2762-2765.